EUR-Lex Access to European Union law

Back to EUR-Lex homepage

This document is an excerpt from the EUR-Lex website

Document 02022R0692-20220503

Consolidated text: Commission Delegated Regulation (EU) 2022/692 of 16 February 2022 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)Text with EEA relevance

ELI: http://data.europa.eu/eli/reg_del/2022/692/2022-05-03

02022R0692 — EN — 03.05.2022 — 000.001


This text is meant purely as a documentation tool and has no legal effect. The Union's institutions do not assume any liability for its contents. The authentic versions of the relevant acts, including their preambles, are those published in the Official Journal of the European Union and available in EUR-Lex. Those official texts are directly accessible through the links embedded in this document

►B

COMMISSION DELEGATED REGULATION (EU) 2022/692

of 16 February 2022

amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures

(Text with EEA relevance)

(OJ L 129 3.5.2022, p. 1)


Corrected by:

►C1

Corrigendum, OJ L 146, 25.5.2022, p.  150 (2022/692)




▼B

COMMISSION DELEGATED REGULATION (EU) 2022/692

of 16 February 2022

amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures

(Text with EEA relevance)



Article 1

Amendments to Regulation (EC) No 1272/2008

Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.

Article 2

Entry into force and application

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

▼C1

It shall apply from 1 December 2023.

▼B

By way of derogation from the second paragraph of this Article, substances and mixtures may be classified, labelled and packaged in accordance with this Regulation from its date of entry into force.

This Regulation shall be binding in its entirety and directly applicable in all Member States.




ANNEX

Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

(1) 

in Part 3, Table 3 is amended as follows:

(a) 

the following entries are inserted:



Index No

Chemical Name

EC No

CAS No

Classification

Labelling

Specific Conc. Limits, M- factors and ATE

Notes

Hazard Class and Category Code(s)

Hazard statement Code(s)

Pictogram, Signal Word Code(s)

Hazard statement Code(s)

Suppl. Hazard statement Code(s)

‘014-052-00-7

silanamine, 1,1,1-trimethyl-N-(trimethylsilyl)-, hydrolysis products with silica; pyrogenic, synthetic amorphous, nano, surface treated silicon dioxide

272-697-1

68909-20-6

STOT RE 2

H373 (lungs) (inhalation)

GHS08

Wng

H373 (lungs) (inhalation)

EUH066’

 

 

‘035-005-00-7

ammonium bromide

235-183-8

12124-97-9

Repr. 1B

Lact.

STOT SE 3

STOT RE 1

Eye Irrit. 2

H360FD

H362

H336

H372 (nervous system)

H319

GHS08

GHS07

Dgr

H360FD

H362

H336

H372 (nervous system)

H319’

 

 

 

‘050-032-00-4

dibutyltin bis(2-ethylhexanoate)

220-481-2

2781-10-4

Muta. 2

Repr. 1B

STOT RE 1

H341

H360FD

H372 (immune system)

GHS08

Dgr

H341

H360FD

H372 (immune system)’

 

 

 

‘050-033-00-X

dibutyltin di(acetate)

213-928-8

1067-33-0

Muta 2

Repr. 1B

STOT RE 1

H341

H360FD

H372 (immune system)

GHS08

Dgr

H341

H360FD

H372 (immune system)’

 

 

 

‘052-001-00-0

tellurium

236-813-4

13494-80-9

Repr. 1B

Lact.

H360Df

H362

GHS08

Dgr

H360Df

H362’

 

 

 

‘052-002-00-6

tellurium dioxide

231-193-1

7446-07-3

Repr. 1B

Lact.

H360Df

H362

GHS08

Dgr

H360Df

H362’

 

 

 

‘056-005-00-3

barium diboron tetraoxide

237-222-4

13701-59-2

Repr. 1B

Acute Tox. 4

Acute Tox. 3

H360FD

H332

H301

GHS08

GHS06

Dgr

H360FD

H332

H301

 

inhalation:

ATE = 1,5 mg/L (dusts or mists)

oral:

ATE = 100 mg/kg bw’

 

‘601-097-00-8

Propylbenzene

203-132-9

103-65-1

Flam. Liq. 3

Asp. Tox. 1

STOT SE 3

Aquatic Chronic 2

H226

H304

H335

H411

GHS02

GHS08

GHS07

GHS09

Dgr

H226

H304

H335

H411’

 

 

 

‘603-243-00-6

2,2-dimethylpropan-1-ol, tribromo derivative; 3-bromo-2,2-bis(bromomethyl)propan-1-ol

253-057-0

36483-57-5; 1522-92-5

Carc. 1B

Muta. 2

H350

H341

GHS08

Dgr

H350

H341’

 

 

 

‘604-096-00-0

piperonyl butoxide (ISO); 2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether

200-076-7

51-03-6

STOT SE 3

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H335

H319

H400

H410

GHS07

GHS09

Wng

H335

H319

H410

EUH066

M = 1

M = 1’

 

‘604-097-00-6

2,4,6-tri-tert-butylphenol

211-989-5

732-26-3

Repr. 1B

Acute Tox. 4

STOT RE 2

Skin Sens. 1B

H360D

H302

H373 (liver)

H317

GHS08

GHS07

Dgr

H360D

H302

H373 (liver)

H317

 

oral:

ATE = 500 mg/kg bw’

 

‘604-098-00-1

4,4'-sulphonyldiphenol; bisphenol S

201-250-5

80-09-1

Repr. 1B

H360FD

GHS08

Dgr

H360FD’

 

 

 

‘606-153-00-5

benzophenone

204-337-6

119-61-9

Carc. 1B

H350

GHS08

Dgr

H350’

 

 

 

‘606-154-00-0

quinoclamine (ISO); 2-amino-3-chloro-1,4-naphthoquinone

220-529-2

2797-51-5

Carc. 2

Repr. 2

Acute Tox. 4

STOT RE 2

Eye Irrit. 2

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 1

H351

H361d

H302

H373 (blood system, kidneys)

H319

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H361d

H302

H373 (blood system, kidneys)

H319

H317

H410

 

oral:

ATE = 500 mg/kg bw

M = 10

M = 10’

 

‘607-756-00-6

exo-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl acrylate; isobornyl acrylate

227-561-6

5888-33-5

Skin Sens. 1A

H317

GHS07

Wng

H317’

 

 

 

‘607-757-00-1

daminozide (ISO); 4-(2,2-dimethylhydrazino)-4-oxobutanoic acid; N-dimethylaminosuccinamic acid

216-485-9

1596-84-5

Carc. 2

H351

GHS08

Wng

H351’

 

 

 

‘607-758-00-7

4,4'-oxydi(benzenesulphonohydrazide)

201-286-1

80-51-3

Self-react. D

Aquatic Acute 1

Aquatic Chronic 1

H242

H400

H410

GHS02

GHS09

Dgr

H242

H410

 

M = 1

M = 1’

 

‘607-759-00-2

toluene-4-sulphonohydrazide

216-407-3

1576-35-8

Self-react. D

H242

GHS02

Dgr

H242’

 

 

 

‘607-760-00-8

2-[N-ethyl-4-[(5-nitrothiazol-2-yl)azo]-m-toluidino]ethyl acetate; C.I. Disperse Blue 124

239-203-6

15141-18-1

Skin Sens. 1A

H317

GHS07

Wng

H317

 

Skin Sens. 1A; H317: C ≥ 0,001 %’

 

‘607-761-00-3

Perfluoroheptanoic acid; tridecafluoroheptanoic acid

206-798-9

375-85-9

Repr. 1B

STOT RE 1

H360D

H372 (liver)

GHS08

Dgr

H360D

H372 (liver)’

 

 

 

‘607-762-00-9

methyl N-(isopropoxycarbonyl)-L-valyl-(3RS)-3-(4-chlorophenyl)-β-alaninate; valifenalate

-

283159-90-0

Carc. 2

Aquatic Chronic 2

H351

H411

GHS08

GHS09

Wng

H351

H411’

 

 

 

‘607-763-00-4

6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid, sodium and tris(2-hydroxyethyl)ammonium salts

-

-

Repr. 1B

Eye Irrit. 2

H360FD

H319

GHS08

GHS07

Dgr

H360FD

H319’

 

 

 

‘607-764-00-X

6-[(C10-C13)-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid

-

2156592-54-8

Repr. 1B

Eye Irrit. 2

H360FD

H319

GHS08

GHS07

Dgr

H360FD

H319’

 

 

 

‘607-765-00-5

6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid

-

-

Repr. 1B

H360FD

GHS08

Dgr

H360FD’

 

 

 

‘613-341-00-0

clofentezine (ISO); 3,6-bis(o-chlorophenyl)-1,2,4,5-tetrazine

277-728-2

74115-24-5

Aquatic Chronic 1

H410

GHS09

Wng

H410

 

M = 1’

 

‘613-342-00-6

theophylline; 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione

200-385-7

58-55-9

Repr. 1B

H360D

GHS08

Dgr

H360D’

 

 

 

‘613-343-00-1

pyridalyl (ISO); 2,6-dichloro-4-(3,3-dichloroallyloxy)phenyl 3-[5-(trifluoromethyl)-2-pyridyloxy]propyl ether

-

179101-81-6

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H317

H400

H410

GHS07

GHS09

Wng

H317

H410

 

M = 1 000

M = 100’

 

‘613-344-00-7

Pyridine-2-thiol 1-oxide, sodium salt; pyrithione sodium; sodium pyrithione

223-296-5;

240-062-8

3811-73-2;

15922-78-8

Acute Tox. 3

Acute Tox. 3

Acute Tox. 4

STOT RE 1

Skin Irrit. 2

Eye Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 2

H331

H311

H302

H372 (nervous system)

H315

H319

H317

H400

H411

GHS06

GHS08

GHS09

Dgr

H331

H311

H302

H372 (nervous system)

H315

H319

H317

H410

EUH070

inhalation:

ATE = 0,5 mg/L (dusts or mists)

dermal:

ATE = 790 mg/kg bw

oral:

ATE = 500 mg/kg bw

M = 100’

 

‘613-345-00-2

1,3,5-triazine-2,4,6-triamine;

melamine

203-615-4

108-78-1

Carc. 2

STOT RE 2

H351

H373 (urinary tract)

GHS08

Wng

H351

H373 (urinary tract)’

 

 

 

‘615-046-00-2

1,3-bis(1-isocyanato-1-methylethyl)benzene; [m-TMXDI]

220-474-4

2778-42-9

Resp. Sens. 1

Skin Sens. 1A

H334

H317

GHS08

Dgr

H334

H317’

 

 

 

‘615-047-00-8

1,3-bis(isocyanatomethyl)benzene; [m-XDI]

222-852-4

3634-83-1

Resp. Sens. 1

Skin Sens. 1A

H334

H317

GHS08

Dgr

H334

H317

 

Skin Sens. 1A; H317: C ≥ 0,001 %’

 

‘615-048-00-3

2,4,6-triisopropyl-m-phenylene diisocyanate

218-485-4

2162-73-4

Resp. Sens. 1

Skin Sens. 1

H334

H317

GHS08

Dgr

H334

H317’

 

 

 

‘615-049-00-9

1,5-naphthylene diisocyanate

[containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]

221-641-4

3173-72-6

STOT SE 3

Skin Irrit. 2

Eye Irrit. 2

Resp. Sens. 1

Skin Sens. 1A

Aquatic Chronic 3

H335

H315

H319

H334

H317

H412

GHS07

GHS08

Dgr

H335

H315

H319

H334

H317

H412’

 

 

 

‘615-050-00-4

1,5-naphthylene diisocyanate

[containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]

221-641-4

3173-72-6

Acute Tox. 2

STOT SE 3

Skin Irrit. 2

Eye Irrit. 2

Resp. Sens. 1

Skin Sens. 1A

Aquatic Chronic 3

H330

H335

H315

H319

H334

H317

H412

GHS06

GHS08

Dgr

H330

H335

H315

H319

H334

H317

H412

 

inhalation:

ATE = 0,27 mg/L (dusts or mists)’

 

‘616-237-00-3

fluopicolide (ISO); 2,6-dichloro-N-[3-chloro-5-(trifluoromethyl)-2-pyridylmethyl]benzamide

-

239110-15-7

Repr. 2

H361d

GHS08

Wng

H361d’

 

 

 

‘616-238-00-9

N-(2-nitrophenyl)phosphoric triamide

477-690-9

874819-71-3

Repr. 1B

STOT RE 2

H360Fd

H373 (kidneys)

GHS08

Dgr

H360Fd

H373 (kidneys)’

 

 

 

‘616-239-00-4

N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide; isoflucypram

-

1255734-28-1

Repr. 2

Acute Tox. 4

Skin Sens. 1B

Aquatic Acute 1

Aquatic Chronic 1

H361f

H332

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H361f

H332

H317

H410

 

inhalation:

ATE = 2,2 mg/L (dusts or mists)

M = 10

M = 1’

 

‘616-240-00-X

Reaction mass of 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9RS)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide and 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9SR)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide [≥ 78 % syn isomers ≤ 15 % anti isomers relative content]; isopyrazam

-

881685-58-1

Carc. 2

Repr. 1B

Skin Sens. 1B

Aquatic Acute 1 Aquatic Chronic 1

H351

H360D

H317

H400

H410

GHS08

GHS07

GHS09

Dgr

H351

H360D

H317

H410

 

Repr. 1B; H360D:

C ≥ 3 %

M = 10

M = 10’

 

‘650-058-00-1

Margosa, ext. [from the kernels of Azadirachta indica extracted with water and further processed with organic solvents]

283-644-7

84696-25-3

Repr. 2

Skin Sens. 1

Aquatic Chronic 1

H361d

H317

H410

GHS08

GHS07

GHS09

Wng

H361d

H317

H410

 

M = 10’

 

(b) 

the entries corresponding to index numbers 014-001-00-9; 023-001-00-8; 601-024-00-X; 603-014-00-0; 603-107-00-6; 604-030-00-0; 607-111-00-9; 607-230-00-6; 607-253-00-1; 607-254-00-7; 607-734-00-6; 607-735-00-1; 607-736-00-7; 608-032-00-2; 609-042-00-X; 613-012-00-1; 616-164-00-7 are replaced by the following entries respectively:



Index No

Chemical Name

EC No

CAS No

Classification

Labelling

Specific Conc. Limits, M- factors and ATE

Notes

Hazard Class and Category Code(s)

Hazard statement Code(s)

Pictogram, Signal Word Code(s)

Hazard statement Code(s)

Suppl. Hazard statement Code(s)

‘014-001-00-9

trichlorosilane

233-042-5

10025-78-2

Flam. Liq. 1

Water-react. 1

Acute Tox. 3

Acute Tox. 4

Skin Corr. 1A

Eye Dam. 1

H224

H260

H331

H302

H314

H318

GHS02

GHS06

GHS05

Dgr

H224

H260

H331

H302

H314

EUH014

EUH029

EUH071

inhalation:

ATE = 7,6 mg/L (vapour)

oral:

ATE = 1 000 mg/kg bw’

 

‘023-001-00-8

divanadium pentaoxide; vanadium pentoxide

215-239-8

1314-62-1

Muta. 2

Carc. 1B

Repr. 2

Lact.

Acute Tox. 3

Acute Tox. 2

STOT SE 3

STOT RE 1

Aquatic Chronic 2

H341

H350

H361fd

H362

H301

H330

H335

H372 (respiratory tract, inhalation)

H411

GHS06

GHS08

GHS09

Dgr

H341

H350

H361fd

H362

H301

H330

H335

H372 (respiratory tract, inhalation)

H411

 

inhalation:

ATE = 0,05 mg/L (dusts or mists)

oral:

ATE = 220 mg/kg bw’

 

‘601-024-00-X

Cumene

202-704-5

98-82-8

Flam. Liq. 3

Carc. 1B

Asp. Tox. 1

STOT SE 3

Aquatic Chronic 2

H226

H350

H304

H335

H411

GHS02

GHS08

GHS07

GHS09

Dgr

H226

H350

H304

H335

H411’

 

 

 

‘603-014-00-0

2-butoxyethanol; ethylene glycol monobutyl ether

203-905-0

111-76-2

Acute Tox. 3

Acute Tox. 4

Skin Irrit. 2

Eye Irrit. 2

H331

H302

H315

H319

GHS06

Dgr

H331

H302

H315

H319

 

inhalation:

ATE = 3 mg/L (Vapours)

oral:

ATE = 1 200 mg/kg bw’

 

‘603-107-00-6

2-(2-methoxyethoxy)ethanol; diethylene glycol monomethyl ether

203-906-6

111-77-3

Repr. 1B

H360D

GHS08

Dgr

H360D

 

Repr. 1B; H360D: C ≥ 3 %’

 

‘604-030-00-0

4,4'-isopropylidenediphenol; bisphenol A

201-245-8

80-05-7

Repr. 1B

STOT SE 3

Eye Dam. 1

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H360F

H335

H318

H317

H400

H410

GHS08

GHS07

GHS05

GHS09

Dgr

H360F

H335

H318

H317

H410

 

M = 1

M = 10’

 

‘607-111-00-9

2-ethyl-2-[[(1-oxoallyl)oxy]methyl]-1,3-propanediyl diacrylate; 2,2-bis(acryloyloxymethyl)butyl acrylate;

trimethylolpropane triacrylate

239-701-3

15625-89-5

Carc. 2

Skin Irrit. 2

Eye Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H315

H319

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H315

H319

H317

H410

 

M = 1

M = 1

D’

‘607-230-00-6

2-ethylhexanoic acid and its salts, with the exception of those specified elsewhere in this Annex

-

-

Repr. 1B

H360D

GHS08

Dgr

H360D’

 

 

 

‘607-253-00-1

cyfluthrin (ISO); α-cyano-4-fluoro-3-phenoxybenzyl-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate

269-855-7

68359-37-5

Lact.

Acute Tox. 2

Acute Tox. 2

STOT SE 1

Aquatic Acute 1

Aquatic Chronic 1

H362

H330

H300

H370 (nervous system)

H400

H410

GHS06

GHS08

GHS09

Dgr

H362

H330

H300

H370 (nervous system)

H410

 

inhalation:

ATE = 0,14 mg/L (dusts or mists)

oral:

ATE = 14 mg/kg bw

M = 1 000 000

M = 1 000 000 ’

 

‘607-254-00-7

beta-cyfluthrin (ISO); reaction mass of rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3S)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate and rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3R)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate

-

1820573-27-0

Lact.

Acute Tox. 2

Acute Tox. 2

STOT SE 1

Aquatic Acute 1

Aquatic Chronic 1

H362

H330

H300

H370 (nervous system)

H400

H410

GHS06

GHS08

GHS09

Dgr

H362

H330

H300

H370 (nervous system)

H410

 

inhalation:

ATE = 0,081 mg/L (dusts or mists)

oral:

ATE = 11 mg/kg bw

M = 1 000 000

M = 1 000 000 ’

 

‘607-734-00-6

pentapotassium 2,2',2",2"',2""-(ethane-1,2-diylnitrilo)pentaacetate

404-290-3

7216-95-7

Repr. 1B

Acute Tox. 4

STOT RE 2

Eye Irrit. 2

H360D

H332

H373 (inhalation)

H319

GHS08

GHS07

Dgr

H360D

H332

H373 (inhalation)

H319

 

Repr. 1B; H360D: C ≥ 3 %

inhalation:

ATE = 1,5 mg/L (dusts or mists)’

 

‘607-735-00-1

N-carboxymethyliminobis(ethylenenitrilo)tetra(acetic acid)

200-652-8

67-43-6

Repr. 1B

Acute Tox. 4

STOT RE 2

Eye Irrit. 2

H360D

H332

H373 (inhalation)

H319

GHS08

GHS07

Dgr

H360D

H332

H373 (inhalation)

H319

 

Repr. 1B; H360D: C ≥ 3 %

inhalation:

ATE = 1,5 mg/L (dusts or mists)’

 

‘607-736-00-7

pentasodium (carboxylatomethyl)iminobis(ethylenenitrilo)tetraacetate

205-391-3

140-01-2

Repr. 1B

Acute Tox. 4

STOT RE 2

H360D

H332

H373 (inhalation)

GHS08

GHS07

Dgr

H360D

H332

H373 (inhalation)

 

Repr. 1B; H360D: C ≥ 3 %

inhalation:

ATE = 1,5 mg/L (dusts or mists)’

 

‘608-032-00-2

acetamiprid (ISO); (1E)-N-[(6-chloropyridin-3-yl)methyl]-N’-cyano-N-methylethanimidamide; (E)-N1-[(6-chloro-3-pyridyl)methyl]-N2-cyano-N1-methylacetamidine

-

135410-20-7 160430-64-8

Repr. 2

Acute Tox. 3

Aquatic Chronic 1

Aquatic Acute 1

H361d

H301

H410

H400

GHS08

GHS06

GHS09

Dgr

H361d

H301

H410

 

oral:

ATE = 140 mg/kg bw

M = 10

M = 10’

 

‘609-042-00-X

pendimethalin (ISO); N-(1-ethylpropyl)-2,6-dinitro-3,4-xylidene

254-938-2

40487-42-1

Repr. 2

Aquatic Acute 1

Aquatic Chronic 1

H361d

H400

H410

GHS08

GSH09

Wng

H361d

H410

 

M = 100

M = 10’

 

‘613-012-00-1

bentazone (ISO); 3-isopropyl-2,1,3-benzothiadiazine-4-one-2,2-dioxide

246-585-8

25057-89-0

Repr. 2

Acute Tox. 4

Eye Irrit. 2

Skin Sens. 1

H361d

H302

H319

H317

GHS08

GHS07

Wng

H361d

H302

H319

H317

 

oral: ATE = 1 600 mg/kg bw’

 

‘616-164-00-7

dimoxystrobin (ISO); (2E)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide; (E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide

 

149961-52-4

Carc. 2

Repr. 2

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H351

H361d

H332

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H361d

H332

H410

 

inhalation:

ATE = 1,3 mg/L (dusts or mists)

M = 100

M = 100’

 

(c) 

the entry corresponding to index number 615-007-00-X is deleted.

Top